A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer.

doi:10.2217/fon-2023-0859

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer.

Future oncology (London, England) - 1 Jan 2024

Riely Gregory J, Smit Egbert F, Ahn Myung-Ju, Felip Enriqueta, Ramalingam Suresh S, Tsao Anne, Johnson Melissa, Gelsomino Francesco, Esper Raymond, Nadal Ernest, Offin Michael, Provencio Mariano, Clarke Jeffrey, Hussein Maen, Otterson Gregory A, Dagogo-Jack Ibiayi, Goldman Jonathan W, Morgensztern Daniel, Alcasid Ann, Usari Tiziana, Wissel Paul, Wilner Keith, Pathan Nuzhat, Tonkovyd Svitlana, Johnson Bruce E

Abstract excerpt

WHAT IS THIS SUMMARY ABOUT?: This is a summary of the results of a study called PHAROS. This study looked at combination treatment with encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®). This combination of medicines was studied in people with metastatic non-small-cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. Metastatic means that the cancer has spread to other parts of the body. All...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzimidazoles

Share to Carbamates

Share to Carcinoma, Non-Small-Cell Lung

Share to Lung Neoplasms

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Source

Open in PubMed

Identifiers

PMID: 38357801
DOI: 10.2217/fon-2023-0859

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer.PMID 38357801Read ↗

Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design.Semantic proximity Read ↗

Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study.Semantic proximity Read ↗

A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report.Semantic proximity Read ↗

Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.Semantic proximity Read ↗

A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Celebrating a breakthrough: FDA endorses encorafenib plus binimetinib alongside two companion diagnostics for BRAV600E mutant metastatic non-small cell lung cancer.Semantic proximity Read ↗

Comparing EGFR tyrosine kinase inhibitor treatments in EGFR-mutated non-small cell lung cancer across Asian and non-Asian patients: a plain language summary.Semantic proximity Read ↗

Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer.Semantic proximity Read ↗

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.